Current filters:


Popular Filters

2026 to 2050 of 2444 results

USA's PDUFA V begins with relatively modest changes to user fee rates


In two Federal Register notices published on August 1, the US Food and Drug Administration announced…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulation

US FDA rejects Regeneron's Arcalyst sBLA for gout flare prevention


US drugmaker Regeneron Pharmaceuticals (Nasdaq: REGN) says that the US Food and Drug Administration issued…

Anti-Arthritics/RheumaticsArcalystBiotechnologyNorth AmericaPharmaceuticalRegeneronRegulation

CytoDyn to acquire Progenics' PRO 140


Development-stage biotech firm CytoDyn (OTCQB: CYDY), has entered into a asset purchase agreement with…

Anti-viralsBiotechnologyCytoDynCytolinPRO 140Progenics Pharmaceuticals

EMA increases interaction with Japanese regulators


The European Medicines Agency has increased its level of interaction and cooperation with medicines regulatory…

Asia-PacificBiotechnologyEuropePharmaceuticalRare diseasesRegulation

New Zealand pharma urged to capturing value from innovation


New Zealand's innovative companies and research community must protect their breakthroughs, for the country…


Genentech gains FDA panel backing for Lucentis to treat DME


US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX), revealed last week that…

BiotechnologyGenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

US FDA clears Amarin's Vascepa, a competitor for Lovaza


The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

Gilead Sciences' 2nd-qtr beats consensus expectations


US biotech firm Gilead Sciences (Nasdaq: GILD), the world's largest marketer of HIV/AIDS drugs, on Friday…

BiotechnologyFinancialGilead Sciences

FDA advisory panel backs approval of ThromboGenics' ocriplasmin for VMA


Belgian biopharmaceutical firm ThromboGenics NV (Euronext Brussels: THR) says that the US Food and Drug…

AlconBiotechnologyNorth AmericaNovartisocriplasminOphthalmicsRegulationThromboGenics

Roche first-half sales and profits beat consensus forecasts


Roche first-half sales and profits beat consensus forecasts


Sanofi 2nd-qtr hit by Plavix competition but group sales still up 6%


French pharma major Sanofi (Euronext: SAN) reported second-quarter 2012 financial results with net sales…


Amgen beats expectations as 2nd-qtr revenues rise 13% and EPS grows 34%


The world's largest independent biotech company, USA-based Amgen (Nasdaq: AMGN), saw its shares move…


Global pharmaceutical approvals moderate as patent cliff peaks, says Fitch


The Food and Drug Administration will approve fewer novel drugs in 2012 compared to 2011 while the industry…

BiotechnologyNorth AmericaPatentsPharmaceuticalRegulation

Batch of clinical trial results for Gilead's elvitegravir, Complera and cobicistat


US biotech firm Gilead Sciences (Nasdaq: GILD), the world's biggest producer of HIV treatments, announced…

Anti-viralsBiotechnologycobicistatCompleraelvitegravirGilead SciencesResearch

Sarepta's shares rocket on positive results with eteplirsen in Duchenne muscular dystrophy


US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares leap 140% to $8.30 yesterday…

AVI BioPharmaBiotechnologyeteplirsenRare diseasesResearchSarepta Therapeutics

UK's NICE to takeover role of assessing high-cost rare disease drugs


In the UK, the role of assessing very high cost drugs for people who suffer with rare conditions, under…

BiotechnologyEuropePharmaceuticalPricingRare diseasesRegulation

Biogen Idec 2nd-qtr sales and earnings top analysts expectations


US biotech firm Biogen (Nasdaq: BIIB) pleased markets with its second-quarter 2012 financial results,…

Biogen IdecBiotechnologyFinancial

Pharma industry calls for broad-based cooperation to fight on-line sales of counterfeit medicines


The global pharmaceutical industry unveiled recommendations this week to tackle the growing public health…

BiotechnologyGenericsGlobalMarkets & MarketingPharmaceuticalRegulation

US govt plans innovative public-private partnerships to turn the tide in fight against HIV/AIDS


In a speech at the opening session of the XIX International AIDS Conference (AIDS 2012) in Washington…

Anti-viralsBiotechnologyHealthcareNorth AmericaPharmaceutical

Onyx soars as FDA approves Kyprolis for multiple myeloma


Shares of US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) leapt 11.7% to $76.38 on Friday, after…

BiotechnologyKyprolisNorth AmericaOncologyOnyx PharmaceuticalsRegulation

Synergy Pharma and Callisto enter merger accord


USA-based biopharma groups Synergy Pharmaceuticals (Nasdaq: SGYP) and Callisto Pharmaceuticals (OTCBB:…

BiotechnologyCallisto PharmaceuticalsMergers & AcquisitionsSynergy Pharmaceuticals

2026 to 2050 of 2444 results

Back to top